New antiviral pill halves risk of COVID-19 hospitalization, Merck says

The study was stopped early due to overwhelming positive results and there is hope the FDA will approve it quickly. 29 days from the start of treatment, 53 patients, or 14.1%, in the placebo group were hospitalized or died due to COVID-19. Among those who received molnupiravir, only 28, or 7.3%, were hospitalized, and no deaths were reported in the group.
Within five days of developing symptoms, the participants were randomly assigned to receive either a five-day course of molnupiravir or a placebo pill, Merck reported. Participants took two pills a day over the five days.



SFC William Farrell Maj Robert ThorntonSGM Steve Wettstein LT Brad McInnis LTC John Griscom PO1 John Johnson Maj William W. 'Bill' PriceSPC Nancy Greene SSG Michael Noll CMSgt Steve Pennington LTC Ken Connolly SGT Ed Matyjasik SFC Joe S. Davis Jr., MSM, DSL PO2 (Join to see) CSM Chuck Stafford SGT Robert Pryor SGT Herbert Bollum SFC (Join to see) Cpl Vic Burk